Efficacy of bortezomib in non-IgM type I cryoglobulinaemic vasculitis: a single-centre retrospective case series.

Hervé LobbesVincent GrobostRichard LemalVirginie RieuGuillaume Le GuennoMarc Ruivard

Published in: European journal of haematology (2018)

Bortezomib in monotherapy should be considered as a valuable option in refractory non-IgM type I CV because of its swift efficacy and acceptable tolerance profile.

Keyphrases

multiple myeloma
newly diagnosed
cross sectional
open label